Specific Antibody toCryptococcus neoformansGlucurunoxylomannan Antagonizes Antifungal Drug Action against Cryptococcal Biofilms In Vitro | Zendy

Luis R. Martinez | Zendy; Eirini Christaki | Zendy; Arturo Casadevall | Zendy

Open Access

Specific Antibody toCryptococcus neoformansGlucurunoxylomannan Antagonizes Antifungal Drug Action against Cryptococcal Biofilms In Vitro

Author(s) -

Luis R. Martinez,

Eirini Christaki,

Arturo Casadevall

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/504722

Subject(s) - cryptococcus neoformans , microbiology and biotechnology , biofilm , antimicrobial , cryptococcosis , cryptococcus , immune system , biology , antibody , in vitro , in vivo , antifungal drug , antifungal , immunology , bacteria , biochemistry , genetics

The fungus Cryptococcus neoformans possesses a polysaccharide capsule and can form biofilms on medical devices. We investigated the efficacy that the combination of a specific antibody to the capsular polysaccharide and antifungal therapy has against cryptococcal biofilms. The antibody enhanced the susceptibility of planktonic cells to antifungal agents, but an antagonistic effect was observed for combination therapy against C. neoformans biofilms. Our findings suggest that antibody therapies for infectious diseases that involve biofilms may antagonize certain antimicrobial therapies, and they also imply that products of the immune response may contribute to drug resistance of biofilms formed in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research